Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 5491465, 11 pages
http://dx.doi.org/10.1155/2016/5491465
Review Article

Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms

1College of Life Sciences, Northwest University, Xi’an, Shaanxi 710069, China
2School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China
3Departments of Medicine, Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA
4Robley Rex Veterans Affairs Medical Center, Louisville, KY 40202, USA

Received 22 September 2015; Revised 6 November 2015; Accepted 8 November 2015

Academic Editor: Paul Enck

Copyright © 2016 Fengyuan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Gao and R. Bataller, “Alcoholic liver disease: pathogenesis and new therapeutic targets,” Gastroenterology, vol. 141, no. 5, pp. 1572–1585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S. A. Borowsky, S. Strome, and E. Lott, “Continued heavy drinking and survival in alcoholic cirrhotics,” Gastroenterology, vol. 80, no. 6, pp. 1405–1409, 1981. View at Google Scholar · View at Scopus
  3. W. Foody, D. D. Heuman, A. A. Mihas, and M. L. Schubert, “Nutritional therapy for alcoholic hepatitis: new life for an old idea,” Gastroenterology, vol. 120, no. 4, pp. 1053–1054, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. T. F. Imperiale and A. J. McCullough, “Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials,” Annals of Internal Medicine, vol. 113, no. 4, pp. 299–307, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Akriviadis, R. Botla, W. Briggs, S. Han, T. Reynolds, and O. Shakil, “Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial,” Gastroenterology, vol. 119, no. 6, pp. 1637–1648, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Naveau, S. Chollet-Martin, S. Dharancy et al., “A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis,” Hepatology, vol. 39, no. 5, pp. 1390–1397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. H. Ki, O. Park, M. Zheng et al., “Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3,” Hepatology, vol. 52, no. 4, pp. 1291–1300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. S. Lieber, “Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases,” Advances in Pharmacology, vol. 38, pp. 601–628, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Mello, E. Ceni, C. Surrenti, and A. Galli, “Alcohol induced hepatic fibrosis: role of acetaldehyde,” Molecular Aspects of Medicine, vol. 29, no. 1-2, pp. 17–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Albano, “Oxidative mechanisms in the pathogenesis of alcoholic liver disease,” Molecular Aspects of Medicine, vol. 29, no. 1-2, pp. 9–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Parola and G. Robino, “Oxidative stress-related molecules and liver fibrosis,” Journal of Hepatology, vol. 35, no. 2, pp. 297–306, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. G. Thurman, B. U. Bradford, Y. Iimuro et al., “The role of gut-derived bacterial toxins and free radicals in alcohol- induced liver injury,” Journal of Gastroenterology and Hepatology, vol. 13, supplement, pp. S39–S50, 1998. View at Google Scholar · View at Scopus
  13. J. I. Beier, G. E. Arteel, and C. J. McClain, “Advances in alcoholic liver disease,” Current Gastroenterology Reports, vol. 13, no. 1, pp. 56–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Mutlu, A. Keshavarzian, P. Engen, C. B. Forsyth, M. Sikaroodi, and P. Gillevet, “Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats,” Alcoholism: Clinical and Experimental Research, vol. 33, no. 10, pp. 1836–1846, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Parlesak, C. Schäfer, T. Schütz, J. C. Bode, and C. Bode, “Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease,” Journal of Hepatology, vol. 32, no. 5, pp. 742–747, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. McLoughlin and K. H. Mills, “Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma,” Journal of Allergy and Clinical Immunology, vol. 127, no. 5, pp. 1097–1109, 2011. View at Publisher · View at Google Scholar
  17. L. Bull-Otterson, W. Feng, I. Kirpich et al., “Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment,” PLoS ONE, vol. 8, no. 1, Article ID e53028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. C. C. Canesso, N. L. Lacerda, C. M. Ferreira et al., “Comparing the effects of acute alcohol consumption in germ-free and conventional mice: the role of the gut microbiota,” BMC Microbiology, vol. 14, article 240, 2014. View at Publisher · View at Google Scholar
  19. A. W. Yan, D. E. Fouts, J. Brandl et al., “Enteric dysbiosis associated with a mouse model of alcoholic liver disease,” Hepatology, vol. 53, no. 1, pp. 96–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. C. Bode, C. Bode, R. Heidelbach, H. K. Dürr, and G. A. Martini, “Jejunal microflora in patients with chronic alcohol abuse,” Hepato-Gastroenterology, vol. 31, no. 1, pp. 30–34, 1984. View at Google Scholar · View at Scopus
  21. C. Bode, R. Kolepke, K. Schafer, and J. Bode, “Breath hydrogen excretion in patients with alcoholic liver disease—evidence of small intestinal bacterial overgrowth,” Zeitschrift fur Gastroenterologie, vol. 31, no. 1, pp. 3–7, 1993. View at Google Scholar · View at Scopus
  22. S. Bhonchal, C. K. Nain, N. Taneja et al., “Modification of small bowel microflora in chronic alcoholics with alcoholic liver disease,” Tropical Gastroenterology, vol. 28, no. 2, pp. 64–66, 2007. View at Google Scholar · View at Scopus
  23. I. A. Kirpich, N. V. Solovieva, S. N. Leikhter et al., “Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study,” Alcohol, vol. 42, no. 8, pp. 675–682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. S. Bajaj, D. M. Heuman, P. B. Hylemon et al., “Altered profile of human gut microbiome is associated with cirrhosis and its complications,” Journal of Hepatology, vol. 60, no. 5, pp. 940–947, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. S. L. Gabbard, B. E. Lacy, G. M. Levine, and M. D. Crowell, “The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth,” Digestive Diseases and Sciences, vol. 59, no. 3, pp. 638–644, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. E. A. Mutlu, P. M. Gillevet, H. Rangwala et al., “Colonic microbiome is altered in alcoholism,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 302, no. 9, pp. G966–G978, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. A. A. I. Fooladi, H. M. Hosseini, M. R. Nourani, S. Khani, and S. M. Alavian, “Probiotic as a novel treatment strategy against liver disease,” Hepatitis Monthly, vol. 13, no. 2, Article ID e7521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. L. O'Mahony, J. Mccarthy, P. Kelly et al., “Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles,” Gastroenterology, vol. 128, no. 3, pp. 541–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. I. A. Kirpich and C. J. McClain, “Probiotics in the treatment of the liver diseases,” Journal of the American College of Nutrition, vol. 31, no. 1, pp. 14–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. W.-H. Lin, C.-F. Hwang, L.-W. Chen, and H.-Y. Tsen, “Viable counts, characteristic evaluation for commercial lactic acid bacteria products,” Food Microbiology, vol. 23, no. 1, pp. 74–81, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Berni Canani, M. Di Costanzo, and L. Leone, “The epigenetic effects of butyrate: potential therapeutic implications for clinical practice,” Clinical Epigenetics, vol. 4, no. 1, article 4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Hass, R. Busche, L. Luciano, E. Reale, and W. V. Engelhardt, “Lack of butyrate is associated with induction of Bax and subsequent apoptosis in the proximal colon of guinea pig,” Gastroenterology, vol. 112, no. 3, pp. 875–881, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. K. Lee and S. Salminen, Handbook of Probiotics and Prebiotics, John Wiley & Sons, New York, NY, USA, 2009.
  34. A. A. Nanji, U. Khettry, and S. M. H. Sadrzadeh, “Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease),” Proceedings of the Society for Experimental Biology and Medicine, vol. 205, no. 3, pp. 243–247, 1994. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Marotta, R. Barreto, C. C. Wu et al., “Experimental acute alcohol pancreatitis-related liver damage and endotoxemia: synbiotics but not metronidazole have a protective effect,” Chinese Journal of Digestive Diseases, vol. 6, no. 4, pp. 193–197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. C. B. Forsyth, A. Farhadi, S. M. Jakate, Y. Tang, M. Shaikh, and A. Keshavarzian, “Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis,” Alcohol, vol. 43, no. 2, pp. 163–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Chang, L. Sang, Y. wang, J. Tong, D. Zhang, and B. Wang, “The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury,” BMC Gastroenterology, vol. 13, article 151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Wang, I. Kirpich, Y. Liu et al., “Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury,” The American Journal of Pathology, vol. 179, no. 6, pp. 2866–2875, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Stadlbauer, R. P. Mookerjee, S. Hodges, G. A. K. Wright, N. A. Davies, and R. Jalan, “Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis,” Journal of Hepatology, vol. 48, no. 6, pp. 945–951, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Loguercio, T. De Simone, A. Federico et al., “Gut-liver axis: a new point of attack to treat chronic liver damage?” American Journal of Gastroenterology, vol. 97, no. 8, pp. 2144–2146, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Loguercio, A. Federico, C. Tuccillo et al., “Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases,” Journal of Clinical Gastroenterology, vol. 39, no. 6, pp. 540–543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. R. K. Dhiman, B. Rana, S. Agrawal et al., “Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial,” Gastroenterology, vol. 147, no. 6, pp. 1327.e3–1337.e3, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Lata, I. Novotný, V. Příbramská et al., “The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study,” European Journal of Gastroenterology and Hepatology, vol. 19, no. 12, pp. 1111–1113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. T. M. Bauer, J. Fernández, M. Navasa, J. Vila, and J. Rodés, “Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis,” Journal of Hepatology, vol. 36, no. 4, pp. 501–506, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Wiest, F. Chen, G. Cadelina, R. J. Groszmann, and G. Garcia-Tsao, “Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension,” Digestive Diseases and Sciences, vol. 48, no. 6, pp. 1136–1141, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Tandon, K. Moncrief, K. Madsen et al., “Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study,” Liver International, vol. 29, no. 7, pp. 1110–1115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Pereg, A. Kotliroff, N. Gadoth, R. Hadary, M. Lishner, and Y. Kitay-Cohen, “Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study,” Nutrition, vol. 27, no. 2, pp. 177–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Yan and D. B. Polk, “Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases,” Gut Microbes, vol. 3, no. 1, pp. 25–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. Zakostelska, M. Kverka, K. Klimesova et al., “Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment,” PLoS ONE, vol. 6, no. 11, Article ID e27961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Nowak, M. Ciszek-Lenda, M. Srottek et al., “Lactobacillus rhamnosus exopolysaccharide ameliorates arthritis induced by the systemic injection of collagen and lipopolysaccharide in DBA/1 mice,” Archivum Immunologiae et Therapiae Experimentalis, vol. 60, no. 3, pp. 211–220, 2012. View at Publisher · View at Google Scholar
  51. F. Yan, L. Liu, P. J. Dempsey et al., “A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor,” The Journal of Biological Chemistry, vol. 288, no. 42, pp. 30742–30751, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Segawa, Y. Wakita, H. Hirata, and J. Watari, “Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice,” International Journal of Food Microbiology, vol. 128, no. 2, pp. 371–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Wang, Y. Liu, A. Sidhu, Z. Ma, C. McClain, and W. Feng, “Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 303, no. 1, pp. G32–G41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Zhao, C. Zhao, Y. Dong et al., “Inhibition of miR122a by Lactobacillus rhamnosus GG culture supernatant increases intestinal occludin expression and protects mice from alcoholic liver disease,” Toxicology Letters, vol. 234, no. 3, pp. 194–200, 2015. View at Publisher · View at Google Scholar
  55. M. Zhang, C. Wang, C. Wang et al., “Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease,” Journal of Nutritional Biochemistry, vol. 26, pp. 337–344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. X. Shi, X. Wei, X. Yin et al., “Hepatic and fecal metabolomic analysis of the effects of Lactobacillus rhamnosus GG on alcoholic fatty liver disease in mice,” Journal of Proteome Research, vol. 14, no. 2, pp. 1174–1182, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Chen, M. Torralba, J. Tan et al., “Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice,” Gastroenterology, vol. 148, no. 1, pp. 203.e16–214.e16, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. W. Zhong and Z. Zhou, “Alterations of the gut microbiome and metabolome in alcoholic liver disease,” World Journal of Gastrointestinal Pathophysiology, vol. 5, no. 4, pp. 514–522, 2014. View at Publisher · View at Google Scholar
  59. T. Sakata, T. Kojima, M. Fujieda, M. Takahashi, and T. Michibata, “Influences of probiotic bacteria on organic acid production by pig caecal bacteria in vitro,” Proceedings of the Nutrition Society, vol. 62, no. 1, pp. 73–80, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Yadav, J.-H. Lee, J. Lloyd, P. Walter, and S. G. Rane, “Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion,” The Journal of Biological Chemistry, vol. 288, no. 35, pp. 25088–25097, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Rescigno, “The intestinal epithelial barrier in the control of homeostasis and immunity,” Trends in Immunology, vol. 32, no. 6, pp. 256–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Rao, “Endotoxemia and gut barrier dysfunction in alcoholic liver disease,” Hepatology, vol. 50, no. 2, pp. 638–644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J. R. Turner, “Intestinal mucosal barrier function in health and disease,” Nature Reviews Immunology, vol. 9, no. 11, pp. 799–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Szabo, “Gut-liver axis in alcoholic liver disease,” Gastroenterology, vol. 148, no. 1, pp. 30–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Spinucci, M. Guidetti, E. Lanzoni, and L. Pironi, “Endogenous ethanol production in a patient with chronic intestinal pseudo-obstruction and small intestinal bacterial overgrowth,” European Journal of Gastroenterology and Hepatology, vol. 18, no. 7, pp. 799–802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Ferrier, F. Bérard, L. Debrauwer et al., “Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents,” The American Journal of Pathology, vol. 168, no. 4, pp. 1148–1154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Hong, S. W. Kim, S. H. Han et al., “Probiotics (Lactobacillus rhamnosus R0011 and acidophilus R0052) reduce the expression of toll-like receptor 4 in mice with alcoholic liver disease,” PLoS ONE, vol. 10, no. 2, Article ID e0117451, 2015. View at Publisher · View at Google Scholar
  68. S. P. Colgan and C. T. Taylor, “Hypoxia: an alarm signal during intestinal inflammation,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 5, pp. 281–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. B. J. Saeedi, D. J. Kao, D. A. Kitzenberg et al., “HIF-dependent regulation of claudin-1 is central to intestinal epithelial tight junction integrity,” Molecular Biology of the Cell, vol. 26, pp. 2252–2262, 2015. View at Google Scholar
  70. D. Ye, S. Guo, R. Alsadi, and T. Y. Ma, “MicroRNA regulation of intestinal epithelial tight junction permeability,” Gastroenterology, vol. 141, no. 4, pp. 1323–1333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Wang, Y. Liu, I. Kirpich et al., “Lactobacillus rhamnosus GG reduces hepatic TNFalpha production and inflammation in chronic alcohol-induced liver injury,” Journal of Nutritional Biochemistry, vol. 24, no. 9, pp. 1609–1615, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Y. Ma, D. Nguyen, V. Bui, H. Nguyen, and N. Hoa, “Ethanol modulation of intestinal epithelial tight junction barrier,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 276, no. 4, pp. G965–G974, 1999. View at Google Scholar · View at Scopus
  73. L. Su, L. Shen, D. R. Clayburgh et al., “Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis,” Gastroenterology, vol. 136, no. 2, pp. 551–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Chen, P. Stärkel, J. R. Turner, S. B. Ho, and B. Schnabl, “Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice,” Hepatology, vol. 61, no. 3, pp. 883–894, 2015. View at Publisher · View at Google Scholar
  75. B. Sun, C. Hu, H. Fang, L. Zhu, N. Gao, and J. Zhu, “The effects of Lactobacillus acidophilus on the intestinal smooth muscle contraction through PKC/MLCK/MLC signaling pathway in TBI mouse model,” PLoS ONE, vol. 10, no. 6, Article ID e0128214, 2015. View at Publisher · View at Google Scholar